3 days popular7 days popular1 month popular3 months popular

Provectus Biopharmaceuticals opens patient enrollment and begins phase 3 international FDA comparative clinical trial of PV-10 for melanoma

Biopharmaceuticals, , a clinical-stage oncology and dermatology biopharmaceutical company, enters phase 3 and has opened enrollment of patients for its phase 3 international comparative clinical trial of PV-10 for . The Company is seeking 225 patients and enrollment has begun at St. Luke’s , Bethlehem, PA, the first study site to be opened, with additional sites to be added in the coming weeks and months.

The study is an international multicenter, open-label, randomized controlled trial (RCT) of single-agent intralesional PV-10 versus systemic chemotherapy with dacarbazine (DTIC) or temozolomide (TMZ) to assess treatment of locally advanced cutaneous melanoma in patients who are BRAF V600 wild-type and have failed or are not otherwise candidates for ipilimumab or another immune checkpoint inhibitor. Subjects in the comparator arm will receive the Investigator’s choice of dacarbazine or temozolomide as determined by Investigator preference and/or local availability of the agent. Effectiveness will be assessed by comparison of progression-free survival (PFS) between all intent-to-treat (ITT) subjects in the two study treatment arms. The Primary Outcome Measure is progression-free survival (PFS) to be assessed every 12 weeks up to 18 months.

The Secondary Outcome Measures include complete response rate (CRR) and its duration (to be assessed every 12 weeks up to 18 months); and Overall survival (OS) to be assessed every 12 weeks up to 18 months.

Safety and tolerability will be assessed by monitoring the frequency, duration, severity and attribution of adverse events and evaluating changes in laboratory values and vital signs. For more details on the study, please visit https://www.clinicaltrials.gov/ct2/show/NCT02288897.

Top-line results from the phase 2 trial have been posted on clinicaltrials.gov, for the study entitled “Phase 2 study of Intralesional PV-10 for Metastatic Melanoma,” [NCT00521053]. https://clinicaltrials.gov/ct2/show/NCT00521053.

For a complete history of Provectus’ research into PV-10 as a treatment for melanoma, visit https://www.pvct.com/pv10melanoma.html

Source

Source: Provectus Biopharmaceuticals, Inc.